{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:28:10Z","timestamp":1793946490684,"version":"4.8.0"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100017596","name":"Natural Science Basic Research Program of Shaanxi Province","doi-asserted-by":"publisher","award":["S2023-JC-QN-1665"],"award-info":[{"award-number":["S2023-JC-QN-1665"]}],"id":[{"id":"10.13039\/501100017596","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017596","name":"Natural Science Basic Research Program of Shaanxi Province","doi-asserted-by":"publisher","award":["2025JC-YBQN-1165"],"award-info":[{"award-number":["2025JC-YBQN-1165"]}],"id":[{"id":"10.13039\/501100017596","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015401","name":"Shaanxi Province Key Research and Development Projects","doi-asserted-by":"publisher","award":["2024SF-GJHX-32"],"award-info":[{"award-number":["2024SF-GJHX-32"]}],"id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.critrevonc.2026.105459","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:42:11Z","timestamp":1782492131000},"page":"105459","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Beyond the \"cold\" barrier: Redefining the clinical paradigm of immune checkpoint inhibitor therapy in ovarian cancer"],"prefix":"10.1016","volume":"226","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2725-8442","authenticated-orcid":false,"given":"Tao","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengchuang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruxing","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahui","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shixue","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianrong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.critrevonc.2026.105459_bib1","doi-asserted-by":"crossref","first-page":"284","DOI":"10.6004\/jnccn.2025.0038","article-title":"NCCN guidelines\u00ae insights: uterine neoplasms, version 3.2025","volume":"23","author":"Abu-Rustum","year":"2025","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105459_bib2","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.6004\/jnccn.2023.0062","article-title":"NCCN Guidelines\u00ae insights: cervical cancer, version 1.2024","volume":"21","author":"Abu-Rustum","year":"2023","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105459_bib3","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.3390\/ijms26051889","article-title":"Circulating tumour DNA for ovarian cancer diagnosis and treatment monitoring: what perspectives for clinical use?","volume":"26","author":"Asante","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105459_bib4","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-024-00932-9","article-title":"Tumour mutational burden: clinical utility, challenges and emerging improvements","volume":"21","author":"Budczies","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105459_bib5","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1172\/JCI123319","article-title":"PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer","volume":"129","author":"Chabanon","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105459_bib6","doi-asserted-by":"crossref","first-page":"7949","DOI":"10.18632\/oncotarget.23742","article-title":"Mutations in DNA repair genes are associated with increased neo-antigen load and activated T cell infiltration in lung adenocarcinoma","volume":"9","author":"Chae","year":"2018","journal-title":"Oncotarget"},{"issue":"10538","key":"10.1016\/j.critrevonc.2026.105459_bib7","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(26)00602-1","article-title":"Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65\/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study","volume":"407","author":"Colombo","year":"2026","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105459_bib8","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1158\/2326-6066.CIR-22-0407","article-title":"The tumor microenvironment of clear-cell ovarian cancer","volume":"10","author":"Devlin","year":"2022","journal-title":"Cancer Immunol. Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105459_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/biom13020339","article-title":"Identification of an autophagy-related signature for prognosis and immunotherapy response prediction in ovarian cancer","volume":"13","author":"Ding","year":"2023","journal-title":"Biomolecules"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105459_bib10","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jamaoncol.2018.6258","article-title":"Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial","volume":"5","author":"Disis","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2026.105459_bib11","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA5500","article-title":"Final results of BrUOG 354: a randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas","author":"Dizon","year":"2024","journal-title":"Am. Soc. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105459_bib12","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1158\/1078-0432.CCR-23-2249","article-title":"Olaparib plus durvalumab, with or without bevacizumab, as treatment in parp inhibitor-na\u00efve platinum-sensitive relapsed ovarian cancer: a phase II multi-cohort study","volume":"30","author":"Drew","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105459_bib13","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jamaoncol.2019.5367","article-title":"Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis","volume":"6","author":"Duan","year":"2020","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105459_bib14","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/s41467-020-15315-8","article-title":"Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer","volume":"11","author":"F\u00e4rkkil\u00e4","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105459_bib15","doi-asserted-by":"crossref","first-page":"4716","DOI":"10.1038\/s41598-025-89270-z","article-title":"Infiltration of CD8+ cytotoxic T-cells and expression of PD-1 and PD-L1 in ovarian clear cell carcinoma","volume":"15","author":"Fu","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2026.105459_bib16","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ygyno.2025.04.513","article-title":"Biomarker-driven targeted therapy in platinum-resistant ovarian cancer: Results from the BRIGHT trial","volume":"200","author":"Gao","year":"2025","journal-title":"Gynecol. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105459_bib17","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41571-024-00937-4","article-title":"Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach","volume":"21","author":"Ghisoni","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"36","key":"10.1016\/j.critrevonc.2026.105459_bib18","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1200\/JCO.24.00668","article-title":"Atezolizumab combined with platinum and maintenance niraparib for recurrent ovarian cancer with a platinum-free interval >6 months: ENGOT-OV41\/GEICO 69-O\/ANITA phase III trial","volume":"42","author":"Gonz\u00e1lez-Mart\u00edn","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105459_bib19","article-title":"Dose-response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer","volume":"3","author":"Goode","year":"2017","journal-title":"JAMA Oncol."},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105459_bib20","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1038\/s41388-018-0581-9","article-title":"Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles","volume":"38","author":"Grabosch","year":"2019","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105459_bib21","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.it.2024.12.006","article-title":"Immune evasion in ovarian cancer: implications for immunotherapy and emerging treatments","volume":"46","author":"Gupta","year":"2025","journal-title":"Trends Immunol."},{"issue":"33","key":"10.1016\/j.critrevonc.2026.105459_bib22","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1200\/JCO.21.00334","article-title":"Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer: open-label, randomized trial in Japan (NINJA)","volume":"39","author":"Hamanishi","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105459_bib23","first-page":"1904","article-title":"CXCL10 and CCL5 as feasible biomarkers for immunotherapy of homologous recombination deficient ovarian cancer","volume":"13","author":"Han","year":"2023","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105459_bib24","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.5545","article-title":"Neoadjuvant combination treatment of olaparib and pembrolizumab for patients with HRD-positive advanced ovarian cancer","author":"Harano","year":"2024","journal-title":"Am. Soc. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105459_bib25","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.annonc.2025.05.009","article-title":"Dostarlimab and niraparib in primary advanced ovarian cancer","volume":"36","author":"Hardy-Bessard","year":"2025","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105459_bib26","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.annonc.2025.11.020","article-title":"Durvalumab with carboplatin\/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer","volume":"37","author":"Harter","year":"2026","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105459_bib27","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S0090-8258(21)00718-6","article-title":"Randomized phase II trial of durvalumab (anti-PDL1) and tremelimumab (anti-CTLA4) administered in combination versus sequentially for the treatment of recurrent platinum-resistant non-clear cell ovarian cancer (NCT03026062)","volume":"162","author":"Hinchcliff","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"21","key":"10.1016\/j.critrevonc.2026.105459_bib28","doi-asserted-by":"crossref","first-page":"5332","DOI":"10.3390\/cancers14215332","article-title":"Tumor-INfiltrating Lymphocytes (TILs) in epithelial ovarian cancer: heterogeneity, prognostic impact, and relationship with immune checkpoints","volume":"14","author":"Hudry","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105459_bib29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ygyno.2023.12.029","article-title":"Durvalumab with or without tremelimumab plus chemotherapy in HRR non-mutated, platinum-resistant ovarian cancer (KGOG 3045): a phase II umbrella trial","volume":"182","author":"Kim","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105459_bib30","doi-asserted-by":"crossref","first-page":"S546","DOI":"10.1016\/j.annonc.2024.08.775","article-title":"713MO Nivolumab and ipilimumab combination treatment in advanced gynaecological clear cell cancers: results from the phase II MoST-CIRCUIT trial","volume":"35","author":"Klein","year":"2024","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105459_bib31","first-page":"451","article-title":"Immune checkpoint inhibitors: breakthroughs in cancer treatment","volume":"21","author":"Kong","year":"2024","journal-title":"Cancer Biol. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105459_bib32","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/jamaoncol.2019.1048","article-title":"Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma","volume":"5","author":"Konstantinopoulos","year":"2019","journal-title":"JAMA Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105459_bib33","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1001\/jamaoncol.2024.6797","article-title":"Pembrolizumab in patients with advanced clear cell gynecological cancer: a phase 2 nonrandomized clinical trial","volume":"11","author":"Kristeleit","year":"2025","journal-title":"JAMA Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105459_bib34","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/s41571-024-00870-6","article-title":"Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno-genomic paradigm for precision medicine","volume":"21","author":"Kumagai","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105459_bib35","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.3389\/fimmu.2023.1292166","article-title":"Limitations and potential of immunotherapy in ovarian cancer","volume":"14","author":"Kumar","year":"2024","journal-title":"Front. Immunol."},{"issue":"30","key":"10.1016\/j.critrevonc.2026.105459_bib36","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1200\/JCO.23.00529","article-title":"Atezolizumab combined with bevacizumab and platinum-based therapy for platinum-sensitive ovarian cancer: placebo-controlled randomized phase III ATALANTE\/ENGOT-ov29 trial","volume":"41","author":"Kurtz","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105459_bib37","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1158\/1078-0432.CCR-22-2032","article-title":"Influence of genomic landscape on cancer immunotherapy for newly diagnosed ovarian cancer: biomarker analyses from the IMagyn050 randomized clinical trial","volume":"29","author":"Landen","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105459_bib38","article-title":"Phase Ib INEOV neoadjuvant trial of durvalumab +\/- tremelimumab with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC): Survival outcomes and immune correlates","volume":"42","author":"Leary","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105459_bib39","doi-asserted-by":"crossref","first-page":"9756","DOI":"10.1038\/s41467-025-64130-6","article-title":"Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial","volume":"16","author":"Lee","year":"2025","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105459_bib40","first-page":"280","article-title":"Epithelial ovarian cancer: Evolution of management in the era of precision medicine","volume":"69","author":"Lheureux","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2026.105459_bib41","article-title":"Immunosuppressive mechanisms and therapeutic targeting of regulatory T cells in ovarian cancer","volume":"16","author":"Li","year":"2025","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105459_bib42","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007802","article-title":"MDSCs-derived GPR84 induces CD8(+) T-cell senescence via p53 activation to suppress the antitumor response","volume":"11","author":"Liu","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105459_bib43","article-title":"BRCA mutations, homologous DNA repair deficiency, tumor mutational burden, and response to immune checkpoint inhibition in recurrent ovarian cancer","volume":"4","author":"Liu","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105459_bib44","doi-asserted-by":"crossref","first-page":"S1170","DOI":"10.1016\/j.annonc.2020.08.2271","article-title":"LBA41 LEAP-005: phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours","volume":"31","author":"Lwin","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105459_bib45","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA5501","article-title":"Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer: final overall and progression-free survival results from the AGO-OVAR 2.29\/ENGOT-ov34 study","author":"Marme","year":"2024","journal-title":"Am. Soc. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105459_bib46","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105459_bib47","article-title":"Exploring the application of PD-1\/PD-L1 inhibitors for ovarian cancer","volume":"46","author":"Miao","year":"2026","journal-title":"Cancer Treat. Res. Commun."},{"issue":"26","key":"10.1016\/j.critrevonc.2026.105459_bib48","doi-asserted-by":"crossref","first-page":"7492","DOI":"10.1016\/j.cell.2024.10.006","article-title":"Ovarian cancer-derived IL-4 promotes immunotherapy resistance","volume":"187","author":"Mollaoglu","year":"2024","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105459_bib49","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S1470-2045(21)00342-9","article-title":"Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial","volume":"22","author":"Monk","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105459_bib50","doi-asserted-by":"crossref","first-page":"S1223","DOI":"10.1016\/j.annonc.2024.08.2269","article-title":"LBA30 ATHENA-COMBO, a phase III, randomized trial comparing rucaparib (RUCA)+ nivolumab (NIVO) combination therapy vs RUCA monotherapy as maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC)","volume":"35","author":"Monk","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105459_bib51","doi-asserted-by":"crossref","first-page":"S457","DOI":"10.1016\/j.ygyno.2026.02.031","article-title":"Immunogenomic determinants of response to immune checkpoint inhibition in ovarian cancer: Insights from the NRG-GY003 clinical trial","volume":"208","author":"Monson","year":"2026","journal-title":"Gynecol. Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105459_bib52","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1200\/JCO.21.00306","article-title":"Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050\/GOG 3015\/ENGOT-OV39)","volume":"39","author":"Moore","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105459_bib53","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1158\/1078-0432.CCR-25-0201","article-title":"Durvalumab versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA\/APGOT-OV2\/GCGS-OV3): a multicenter, randomized, phase 2 trial","volume":"31","author":"Ngoi","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105459_bib54","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1470-2045(25)00662-X","article-title":"Pembrolizumab plus lenvatinib in recurrent gynaecological clear cell carcinoma (LARA): a multicentre, single-arm, phase 2 trial","volume":"27","author":"Ngoi","year":"2026","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105459_bib55","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41698-026-01287-3","article-title":"Ultrasensitive ctDNA monitoring reveals early predictors of immunotherapy response in advanced cancer","volume":"10","author":"Nishizaki","year":"2026","journal-title":"npj Precis. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105459_bib56","article-title":"Ultrasensitive ctDNA monitoring reveals early predictors of immunotherapy response in advanced cancer","volume":"10","author":"Nishizaki","year":"2026","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105459_bib57","article-title":"Immune checkpoint inhibitors in clear cell ovarian carcinoma and mixed gynecologic clear cell cohorts: a systematic review and meta-analysis","author":"Noronha","year":"2026","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105459_bib58","doi-asserted-by":"crossref","first-page":"A4","DOI":"10.1136\/ijgc-2023-IGCS.5","volume":"33","author":"O\u2019Cearbhaill","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105459_bib59","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000438","article-title":"ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1\/PD-L1 immunotherapy","volume":"8","author":"Okamura","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105459_bib60","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009058","article-title":"Unique immune characteristics and differential anti-PD-1-mediated reinvigoration potential of CD8(+) TILs based on BRCA1\/2 mutation status in epithelial ovarian cancers","volume":"12","author":"Park","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105459_bib61","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007444","article-title":"Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046\/TRU-D","volume":"11","author":"Park","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105459_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1661048","article-title":"The immunotherapy era in ovarian clear cell carcinoma: current evidence and future perspective","volume":"16","author":"Passarelli","year":"2025","journal-title":"Front. Immunol."},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105459_bib63","doi-asserted-by":"crossref","first-page":"10859","DOI":"10.3390\/ijms241310859","article-title":"Current understanding on why ovarian cancer is resistant to immune checkpoint inhibitors","volume":"24","author":"Paw\u0142owska","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105459_bib64","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S1470-2045(24)00437-6","article-title":"Sintilimab combined with bevacizumab in relapsed or persistent ovarian clear cell carcinoma (INOVA): a multicentre, single-arm, phase 2 trial","volume":"25","author":"Peng","year":"2024","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105459_bib65","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","article-title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study","volume":"22","author":"Pujade-Lauraine","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2026.105459_bib66","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ygyno.2023.10.005","article-title":"Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a phase II study (MOONSTONE\/GOG-3032)","volume":"178","author":"Randall","year":"2023","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105459_bib67","doi-asserted-by":"crossref","first-page":"5931","DOI":"10.1038\/s41467-024-46999-x","article-title":"Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial","volume":"15","author":"Ray-Coquard","year":"2024","journal-title":"Nat. Commun."},{"issue":"6230","key":"10.1016\/j.critrevonc.2026.105459_bib68","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105459_bib69","article-title":"Ovarian cancer","volume":"12","author":"Scott","year":"2026","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105459_bib70","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1158\/0008-5472.CAN-18-1003","article-title":"PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness","volume":"79","author":"Shen","year":"2019","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105459_bib71","doi-asserted-by":"crossref","first-page":"8899","DOI":"10.1038\/s41598-023-35092-w","article-title":"Genomic and molecular landscape of homologous recombination deficiency across multiple cancer types","volume":"13","author":"Shi","year":"2023","journal-title":"Sci. Rep."},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105459_bib72","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1016\/j.molcel.2025.08.030","article-title":"Activation and regulation of cGAS-STING signaling in cancer cells","volume":"85","author":"Shim","year":"2025","journal-title":"Mol. Cell."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105459_bib73","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13000-023-01358-0","article-title":"A comprehensive molecular analysis of 113 primary ovarian clear cell carcinomas reveals common therapeutically significant aberrations","volume":"18","author":"Stru\u017einsk\u00e1","year":"2023","journal-title":"Diagn. Pathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105459_bib74","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-026-70785-6","article-title":"Durvalumab and cediranib with and without olaparib in recurrent ovarian cancer: a phase II proof-of-concept study","volume":"17","author":"Tabata","year":"2026","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105459_bib75","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1002\/1878-0261.13811","article-title":"Peripheral blood leukocyte signatures as biomarkers in relapsed ovarian cancer patients receiving combined anti-CD73\/anti-PD-L1 immunotherapy in arm A of the NSGO-OV-UMB1\/ENGOT-OV30 trial","volume":"19","author":"Tandaric","year":"2025","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105459_bib76","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.e17552","article-title":"An open, prospective, single arm, phase II study of cadonilimab (PD-1\/CTLA-4 bispecific antibody) with neoadjuvant chemotherapy in patients with advanced ovarian cancer: Interim analysis from the AK104-IIT-003 study","author":"Tang","year":"2024","journal-title":"Am. Soc. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105459_bib77","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1158\/1078-0432.CCR-15-2518","article-title":"VEGF potentiates GD3-mediated immunosuppression by human ovarian cancer cells","volume":"22","author":"Tiper","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105459_bib78","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41416-019-0654-8","article-title":"Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers","volume":"122","author":"Tuna","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"7941","key":"10.1016\/j.critrevonc.2026.105459_bib79","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41586-022-05496-1","article-title":"Ovarian cancer mutational processes drive site-specific immune evasion","volume":"612","author":"V\u00e1zquez-Garc\u00eda","year":"2022","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105459_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2025.101704","article-title":"Chemotherapy with or without pembrolizumab followed by maintenance with olaparib or placebo for first-line treatment of advanced BRCA non-mutated epithelial ovarian cancer: results from the randomized phase 3 ENGOT-OV43\/GOG-3036\/KEYLYNK-001 study","volume":"35","author":"Vergote","year":"2025","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105459_bib81","first-page":"308","article-title":"Cancer treatment and survivorship statistics, 2025","volume":"75","author":"Wagle","year":"2025","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105459_bib82","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1186\/s12967-025-06508-0","article-title":"Role of tumor microenvironment in ovarian cancer metastasis and clinical advancements","volume":"23","author":"Wang","year":"2025","journal-title":"J. Transl. Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105459_bib83","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13092249","article-title":"Homologous recombination repair deficiency and implications for tumor immunogenicity","volume":"13","author":"van Wilpe","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105459_bib84","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/S0090-8258(22)01399-3","article-title":"Threshold of tumor mutational burden and association with survival in ovarian cancer (172)","volume":"166","author":"Wu","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105459_bib85","doi-asserted-by":"crossref","DOI":"10.5772\/intechopen.1005693","article-title":"Cancer-associated fibroblasts in ovarian cancer: research progress","volume":"15","author":"Xu","year":"2025","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105459_bib86","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1136\/ijgc-2024-005351","article-title":"Biomarker-driven targeted therapy in patients with recurrent platinum-resistant epithelial ovarian cancer (BRIGHT): protocol for an open-label, multicenter, umbrella study","volume":"34","author":"Xu","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105459_bib87","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20205129","article-title":"Relationship between microsatellite instability, immune cells infiltration, and expression of immune checkpoint molecules in ovarian carcinoma: immunotherapeutic strategies for the future","volume":"20","author":"Yamashita","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105459_bib88","doi-asserted-by":"crossref","first-page":"10045","DOI":"10.1002\/cam4.5590","article-title":"Peripheral and tumor-infiltrating immune cells are correlated with patient outcomes in ovarian cancer","volume":"12","author":"Zhang","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.critrevonc.2026.105459_bib89","first-page":"2025","article-title":"Gut microbiome alterations and their clinical and biological implications in ovarian cancer: a systematic review","volume":"15","author":"Zhang","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105459_bib90","article-title":"cGAS\/STING signaling pathway in gynecological malignancies: From molecular mechanisms to therapeutic values","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105459_bib91","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/jamaoncol.2020.5945","article-title":"Efficacy and safety of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of recurrent ovarian cancer: a phase 2 nonrandomized clinical trial","volume":"7","author":"Zsiros","year":"2021","journal-title":"JAMA Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282600346X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282600346X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:36:25Z","timestamp":1793943385000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084282600346X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":91,"alternative-id":["S104084282600346X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105459","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond the \"cold\" barrier: Redefining the clinical paradigm of immune checkpoint inhibitor therapy in ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105459","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105459"}}